7 Things to Know About the DURYSTA Implant

DURYSTA at a glance: what it is and what it treats

DURYSTA is a prescription, biodegradable implant containing 10 micrograms of bimatoprost. “Intracameral” means it is placed in the anterior chamber—the fluid-filled space at the front of the eye between the cornea and iris. The implant is approximately 1 millimeter long and comes in a preloaded, single-use applicator. An eye doctor administers it directly into the eye rather than asking the patient to apply medication to the eye’s surface every day.

Its purpose is specific: lowering intraocular pressure in people with open-angle glaucoma or ocular hypertension. It is not a treatment for dry eye. Reducing the daily glaucoma-drop burden may nevertheless matter to someone whose topical medication contributes to ocular-surface discomfort, but that is different from treating the underlying dry-eye condition. The dose, indication, size, delivery method, and one-administration-per-eye limit appear in the manufacturer’s DURYSTA clinical FAQ.

DURYSTA is intended to control an important glaucoma risk factor: pressure inside the eye. Some patients may use fewer drops while the implant is effective, but implantation does not guarantee freedom from every glaucoma medication. Additional drops, laser treatment, or a glaucoma procedure may still be needed if the achieved pressure is not low enough or the benefit later declines.

The defining limitation is easy to miss in descriptions of DURYSTA as “dissolvable”: under current manufacturer labeling information, each eye may receive DURYSTA only once. It must not be readministered to an eye that has already received it. Biodegradation does not make the treatment renewable.

General-information notice: Only an ophthalmologist who knows your diagnosis, glaucoma severity, target pressure, corneal health, drainage-angle anatomy, lens and lens-capsule status, and previous treatment history can determine whether DURYSTA is appropriate. This article cannot assess individual candidacy or replace an eye examination.

When considering the implant, it is more useful to ask, “Could one administration help this eye reach its target pressure with an acceptable level of risk?” than, “Can this permanently replace my drops?” The first question reflects what DURYSTA may offer. The second assumes permanence and repeatability that the treatment does not provide.

How sustained bimatoprost delivery lowers eye pressure

The front of the eye continuously produces a clear fluid called aqueous humor. This fluid circulates through the anterior chamber and leaves through drainage pathways near the angle where the iris and cornea meet. If drainage is inadequate relative to production, pressure can rise.

Bimatoprost is a prostaglandin analog. It is believed to lower pressure primarily by increasing aqueous-humor outflow through two routes: the conventional trabecular-meshwork pathway and the uveoscleral pathway. DURYSTA places bimatoprost in a solid polymer matrix inside the anterior chamber, allowing sustained delivery near the eye’s drainage structures rather than depending on repeated application to the ocular surface. A peer-reviewed first-approval review of the bimatoprost implant describes its construction, proposed pressure-lowering mechanism, delivery system, and biodegradation.

As medication is released, the polymer gradually breaks down into lactic and glycolic acids. Because the implant biodegrades, routine surgical removal is generally unnecessary.

“Biodegradable,” however, does not mean “risk-free.” Bypassing the ocular surface avoids applying this particular medication topically each day and may reduce the burden of remembering or administering drops. Intracameral delivery introduces different concerns, including an invasive administration procedure, inflammation, implant movement, corneal effects, infection risk, and limited ability to alter treatment after placement.

That loss of day-to-day adjustability is one of the central tradeoffs of sustained delivery.

Minimal systemic exposure was reported after one implant in approval-era clinical data. That finding does not establish that DURYSTA is safer overall than topical treatment. Overall safety includes both systemic and eye-specific risks, and the implant’s intraocular risks differ from those of drops.

How much pressure reduction was shown—and how long it may last

In two Phase 3 studies, a single DURYSTA administration reduced intraocular pressure by approximately 5–8 mm Hg from a mean baseline of 24.5 mm Hg. That absolute reduction corresponds to roughly 20%–33% of the reported baseline; it should not be simplified to an expectation that every patient will receive a 30% reduction. The primary efficacy assessments occurred through Week 12 and compared the implant with twice-daily topical timolol 0.5%. The Glaucoma Research Foundation reports that DURYSTA’s pressure reduction was statistically non-inferior to timolol during that assessment period in the cited trials (sustained-release glaucoma treatment overview).

Manufacturer material also describes a mean pressure reduction of 5–8 mm Hg over approximately 15 weeks, while its efficacy footnote identifies measurements at Weeks 2, 6, and 12. These descriptions reflect different presentations of the study window. The most cautious conclusion is that meaningful average pressure reduction was demonstrated during the first several months, with the stated primary assessments conducted through Week 12.

The studies do not establish superiority over every glaucoma treatment. The comparator was timolol 0.5% used twice daily—not every prostaglandin drop, combination medication, selective laser trabeculoplasty, minimally invasive glaucoma surgery, or conventional glaucoma operation.

An average result also cannot predict what will happen in a particular eye. A fall from 25 to 19 mm Hg might be useful for one person but inadequate for someone with advanced disease and a much lower target.

Three timelines are often blurred together:

1. Medication-release duration: how long clinically relevant bimatoprost is released.
2. Biodegradation time: how long the polymer material takes to break down.
3. Pressure-lowering duration: how long intraocular pressure remains adequately controlled.

These timelines are not interchangeable. Conversely, an eye may remain below its intervention threshold for a period after most active drug delivery has ended. The practical expectation is medication delivery and pressure lowering for several months, with substantial variation between patients, rather than a guaranteed expiration date.

Longer-lasting control has been reported in subsets of study participants, including control extending into the 12–24-month range. These observations are not a guarantee of comparable duration for an individual patient. Some longer-term research also evaluated doses or repeated-administration regimens that differ from the current single-administration approach, as an EyeWorld report on early experience and durability explains.

The endpoint also matters. Requiring no additional pressure-lowering treatment during follow-up is not necessarily the same as maintaining the original 5–8 mm Hg reduction. A patient may avoid rescue treatment because pressure remains below a clinician-defined threshold even after some of the initial effect has faded.

Duration should therefore be judged through serial pressure measurements and the health of the optic nerve and visual field—not merely by how long someone stays off a particular bottle. Relevant questions include:

• Did the implant bring the eye to its individualized target pressure?
• How stable was that pressure between visits?
• Is structural or visual-field damage continuing?
• When would the ophthalmologist add or restart treatment?
• What will be used next, given that the implant cannot be repeated in that eye?

A marketing duration or trial average is less useful than repeated measurements interpreted in the context of the patient’s disease.

Who may be considered—and who should not receive DURYSTA

The labeled population consists of patients with open-angle glaucoma or ocular hypertension who need lower intraocular pressure. Within that population, an ophthalmologist might discuss sustained delivery with someone who frequently forgets drops, cannot handle a bottle easily, relies on a caregiver for administration, or has difficulty tolerating topical medication.

Those practical problems can justify a conversation, but they do not establish candidacy. A person can have an adherence problem and also have an eye finding that makes DURYSTA inappropriate.

Manufacturer safety information lists the following contraindications—circumstances in which DURYSTA should not be used:

• Active or suspected infection in or around the eye
• Corneal endothelial-cell dystrophy
• A previous corneal transplant or endothelial-cell transplant
• An absent or ruptured posterior lens capsule
• Hypersensitivity to bimatoprost or another product component

The same safety information identifies cautions involving limited endothelial-cell reserve, narrow or obstructed angles, certain lens conditions, macular-edema risk, and intraocular inflammation (DURYSTA uses and safety information).

Why corneal endothelial health matters

The cornea is the transparent tissue at the front of the eye. Its innermost layer consists of endothelial cells that help pump fluid out of the cornea and keep it clear. If too few functional cells remain, the cornea can swell and lose transparency.

Because DURYSTA sits in the anterior chamber near the cornea and has been associated with endothelial-cell loss, the health and reserve of this cell layer are central to candidacy. A history of endothelial dystrophy or corneal transplantation is not merely a minor consideration; it falls within the listed contraindications.

The ophthalmologist must interpret corneal findings in the context of the whole eye and the expected benefit.

Anatomy and medical history that require caution

Other findings may require particular caution and individualized judgment rather than automatic approval or rejection:

• Limited corneal endothelial-cell reserve
• A narrow iridocorneal angle or scarring that could obstruct where the implant is intended to settle
• Aphakia, meaning no natural lens is present
• Certain artificial-lens situations, particularly when the posterior capsule is torn
• Risk factors for macular edema
• Active inflammation inside the eye

The posterior lens capsule is the thin structure behind the lens. If it is absent or torn, an implant placed in the front of the eye may migrate toward the posterior segment. That migration concern is why an absent or ruptured posterior capsule is listed as a contraindication rather than a routine anatomical variation.

Safety and effectiveness have not been established in pediatric patients.

Candidacy checklist for an ophthalmology visit

Before deciding, ask the clinician to review:

• The exact diagnosis: open-angle glaucoma, ocular hypertension, or another condition
• The stage and rate of progression
• The target pressure for each eye
• Current and previous pressure-lowering treatments
• Previous response to bimatoprost or a related medication
• Corneal clarity and endothelial health
• Anterior-chamber and drainage-angle anatomy
• Natural or artificial lens status
• Whether the posterior lens capsule is intact
• Previous corneal, cataract, lens, retinal, or glaucoma surgery
• Current or recent eye infection
• Current or recurrent intraocular inflammation
• Macular-edema history or risk factors
• Whether current drops would continue after implantation
• The backup plan if the pressure response is insufficient

Candidacy is not simply a choice between “drops” and “no drops.” It is a risk-benefit decision involving the cornea, internal anatomy, required pressure reduction, disease severity, and available alternatives.

Why the same eye can receive DURYSTA only once

DURYSTA treatment is limited to one implant per eye, and it must not be readministered to an eye that has already received the product under current manufacturer labeling information.

The restriction is closely tied to corneal safety. Research programs initially evaluated repeated administrations, but repeated exposure raised concern about progressive loss of corneal endothelial cells and potential corneal damage. The Glaucoma Research Foundation identifies this concern as the reason DURYSTA is limited to one administration (independent DURYSTA summary).

This limitation changes how the treatment should be understood. DURYSTA is not analogous to a renewable contact lens, a routinely scheduled injection, or a device that can simply be replaced after it dissolves. It is one finite treatment opportunity within a long-term pressure-control plan.

Biodegradation does not reset eligibility. Even after the polymer has broken down, the previous implant still counts as the one administration permitted for that eye. The restriction concerns the effects of repeated treatment on ocular tissues, not merely whether physical implant material remains visible.

“One implant per eye” also does not mean “one glaucoma treatment for life.” Open-angle glaucoma and ocular hypertension still require ongoing examinations, pressure measurements, and treatment decisions. If the benefit diminishes, a clinician may consider:

• Restarting, continuing, or changing topical medication
• Selective laser trabeculoplasty
• A minimally invasive or conventional glaucoma procedure
• Other pressure-lowering strategies appropriate to the diagnosis and anatomy

No universal sequence is right for every patient. Someone with mild disease and a modest pressure target may have different options from a person with advanced visual-field loss who needs very low pressure.

The post-DURYSTA strategy should be discussed before implantation. Useful questions include:

• Will I continue any existing drops immediately after treatment?
• What pressure would count as an adequate response?
• At what pressure or evidence of progression would you add treatment?
• Which options remain if the effect lasts only a few months?
• Would laser still be available?
• Could my disease severity make surgery more appropriate?
• How will you recognize that the benefit is fading?

The cited clinical studies did not administer DURYSTA to both eyes at the same visit. That fact does not prove same-day bilateral treatment is unsafe, but it means those studies do not establish its safety. If both eyes could otherwise qualify, ask the ophthalmologist how and why treatment would be staged.

What treatment day and follow-up may involve

A trained eye doctor administers DURYSTA into the anterior chamber using a preloaded, single-use applicator. Administration is performed under magnification and aseptic conditions, with the patient’s head stabilized. Published administration guidance says the eye should not be dilated beforehand. Treatment may take place in an appropriately equipped medical office or ambulatory surgery center.

The available evidence does not support a universal promise that implantation is painless, always takes a specific number of minutes, requires no preparation, or has no recovery period. Individual experience and clinic protocols can vary.

After administration, the patient should remain upright for at least one hour so the implant can settle into the lower portion of the anterior-chamber angle. The clinician should monitor the eye for its pressure response, inflammation, implant position, corneal effects, and other complications. These instructions are described in the manufacturer’s professional DURYSTA information.

Follow-up is not optional simply because the medication is released automatically. The implant reduces the need to remember a dose; it does not remove the need to determine whether that dose is working safely.

Before treatment, request individualized instructions about:

• What numbing medicine, if any, will be used
• Whether someone should drive you home
• Whether to use your usual glaucoma drops that morning
• Which medications to use afterward
• When you may return to work
• Whether exercise, bending, lifting, swimming, or eye rubbing should be restricted
• When the first pressure check will occur
• How often the cornea and implant position will be assessed
• Which telephone number to use after hours

Do not assume that DURYSTA automatically replaces every current drop. The ophthalmologist may continue, change, or stop particular medications based on the pressure response and treatment plan. Confirm the instructions for each bottle by name and for each eye.

Practical appointment checklist

Bring or verify:

• A complete medication list, including eye drops and non-eye medicines
• Medication and material allergies
• A history of previous eye operations, especially corneal, cataract, lens, retinal, or glaucoma surgery
• Details of any corneal transplant or endothelial procedure
• Recent redness, discharge, pain, light sensitivity, or change in vision
• Your target pressure, if known
• Recent pressure and visual-field results
• Insurance authorization status
• Expected implant, procedure, facility, testing, and follow-up charges
• Written instructions for your drops
• The plan if DURYSTA does not lower pressure enough

After implantation, record symptoms and follow the clinic’s schedule even if the eye feels normal.

Common side effects, serious risks, and warning signs

Eye redness—technically called conjunctival hyperemia—was the most common adverse reaction in the cited Phase 3 studies and occurred in approximately 27% of participants. Other reactions reported in 5%–10% included foreign-body sensation, eye pain, light sensitivity, conjunctival hemorrhage, dry eye, irritation, increased intraocular pressure, corneal endothelial-cell loss, blurred vision, iritis, and headache, according to the DURYSTA healthcare-professional safety FAQ.

These percentages do not mean every event is equally serious. Redness or irritation may be relatively common, while a less frequent complication can pose a greater threat to vision.

Clinically important risks

Corneal endothelial-cell loss: Progressive loss of the cells that keep the cornea clear can lead to corneal swelling and impaired vision. This risk is particularly important for people who begin with limited endothelial reserve and is central to the prohibition on repeat administration.

Implant migration: The implant is intended to settle in the inferior angle at the front of the eye. Certain anatomical conditions—especially an absent or torn posterior lens capsule—can allow movement toward the back of the eye.

Macular edema: Fluid can accumulate in the macula, the central retinal area responsible for detailed vision. Certain lens conditions and other risk factors increase concern.

Intraocular inflammation: DURYSTA may cause inflammation inside the eye or aggravate existing inflammation.

Iris pigmentation: Bimatoprost can increase brown pigmentation of the iris, and the color change is considered likely to be permanent.

Endophthalmitis: Procedures and injections that enter the eye carry a risk of serious internal eye infection. This is different from mild surface irritation and requires urgent clinical evaluation. These risks and associated precautions are summarized in the manufacturer’s patient safety information.

Because the implant is biodegradable, it generally does not require routine removal. But “no routine removal” does not mean every complication can be managed by waiting for it to dissolve. Migration, inflammation, corneal injury, or another unexpected finding may require individualized intervention.

Warning after treatment

Contact your treating eye doctor promptly if you develop eye pain, marked or worsening redness, light sensitivity, or any change in vision after DURYSTA.

Do not assume redness, dryness, or irritation is harmless when it occurs with pain, photophobia, or altered vision after a procedure inside the eye. Sudden vision change, pain, or light sensitivity warrants same-day clinical attention rather than self-treatment based on an online article. This article is general information, consistent with Dry Eye Watch’s medical-information boundary.

If the treating practice gave you an emergency number, use it. If you cannot reach the practice and symptoms are severe or vision changes suddenly, seek urgent eye care rather than waiting for a routine follow-up.

DURYSTA versus drops, laser, and glaucoma procedures

There is no single best glaucoma treatment for every patient. A useful comparison considers dosing burden, invasiveness, adjustability, repeatability, ocular-surface exposure, procedural risks, monitoring requirements, and how closely the available evidence matches the individual’s situation.

Consideration	DURYSTA	Topical drops	Laser or glaucoma procedures
Dosing burden	No daily self-administration while the implant provides sufficient control	Requires repeated dosing according to the prescription	The procedure itself does not require daily administration, although medication may still be needed
Delivery	Medication is released inside the anterior chamber	Medication is applied to the ocular surface	Uses a procedure intended to lower pressure
Invasiveness	Requires intracameral administration	Usually noninvasive self-administration	Varies substantially by laser or surgical category
Adjustability	Cannot be adjusted or stopped at home after placement	Can be continued, stopped, switched, or combined under clinical direction	Depends on the procedure and subsequent options
Repeatability	Only once per eye under current labeling information	Generally ongoing and modifiable	Depends on the specific laser or operation
Duration	Variable; generally several months, with longer control reported in some participants	Depends on continuing the prescribed schedule	Varies by procedure and patient
Main practical advantage	Reduces daily dosing burden for a finite period	Familiar and adjustable; no implant required	May provide another route to achieving the target pressure
Main tradeoff	Corneal and intraocular risks, variable duration, and no retreatment in the same eye	Adherence demands and possible medication or ocular-surface effects	Procedure-specific risks, recovery, monitoring, and uncertain individual response

This table is a decision framework, not evidence that one category is superior or that any procedure will eliminate medication.

DURYSTA

DURYSTA offers sustained intracameral delivery without daily administration during the period when it provides adequate control. It bypasses daily topical exposure, but it cannot be readministered in the same eye or easily adjusted after placement. Its duration varies, and corneal and other intraocular risks must be weighed against convenience.

Topical glaucoma drops

Drops are adjustable. A clinician can change the drug, schedule, or combination as the disease and response evolve. Their main practical disadvantage is the need for repeated correct administration. Some patients forget doses, have trouble squeezing or aiming a bottle, depend on another person, or experience ocular-surface symptoms.

That does not mean all glaucoma drops cause dry eye or that everyone with surface discomfort should receive an implant. Symptoms may depend on the medication, preservative, dosing frequency, technique, underlying ocular-surface disease, and other factors. Adjusting the drop regimen may be an alternative worth discussing.

Selective laser trabeculoplasty and surgery

Selective laser trabeculoplasty, minimally invasive glaucoma surgery, and conventional glaucoma surgery are different treatment categories, not interchangeable versions of DURYSTA. Their expected pressure reduction, risks, recovery, repeatability, and suitability depend on the particular procedure and eye.

The strongest head-to-head evidence described here compares DURYSTA with twice-daily timolol over a short primary assessment period. It does not establish that DURYSTA is superior to modern prostaglandin drops, laser, minimally invasive procedures, or conventional surgery.

Early physician reports described possible value for patients with ocular-surface disease or difficulty remembering or administering drops. Those observations help explain how some clinicians initially approached patient selection, but they are anecdotal impressions rather than comparative-effectiveness evidence (EyeWorld’s early physician-experience report).

A balanced choice should account for:

• The target pressure
• Glaucoma severity and rate of progression
• Previous response to medication or laser
• Corneal endothelial health
• Drainage-angle and lens anatomy
• Ability to administer drops reliably
• Ocular-surface tolerance
• Willingness to undergo an intraocular procedure
• Need for adjustable or repeatable treatment
• Available options after DURYSTA’s effect declines

The best fit may differ even between a person’s two eyes.

Cost, coverage, and questions to ask before agreeing

The final amount can involve several components:

• The implant
• The administration procedure
• Office or ambulatory-surgery-center charges
• Examination and imaging
• Corneal assessment
• Pressure checks
• Follow-up care
• Other treatment if the target pressure is not reached

Do not assume that coverage of the implant automatically includes every professional, facility, testing, or follow-up charge.

The manufacturer advertises a savings program under which some eligible commercially insured adults may pay as little as $0 for an implant, subject to program rules, limits, legal restrictions, and possible change or termination. The offer is not insurance. People receiving reimbursement through government-funded programs such as Medicare, Medicaid, TRICARE, Department of Defense programs, or Veterans Affairs generally are not eligible under the described terms (DURYSTA patient and savings information).

Administration, facility, examination, testing, and follow-up charges may be separate.

Contact the clinic and insurer independently. Ask the insurer:

• Is prior authorization required?
• Is DURYSTA covered under the medical benefit, pharmacy benefit, or another category?
• Are the doctor and facility in network?
• Is the administration procedure covered separately?
• What deductible, copayment, or coinsurance applies?
• Are corneal testing and follow-up pressure checks covered?
• Is a documented trial of other treatments required?

Ask the clinic:

• What billing codes will be submitted?
• Is there a separate facility fee?
• What is the estimated total, not only the implant price?
• Which follow-up visits are included?
• Could corneal imaging or cell assessment generate separate charges?
• What happens financially if authorization is denied?
• What costs could arise if another treatment is needed soon afterward?

The manufacturer also maintains a directory of clinicians reported to have DURYSTA experience. The directory may help identify practices to contact, but the manufacturer says it may be incomplete or outdated. Inclusion does not independently establish current availability, expertise, quality, or suitability for a particular patient.

Before agreeing, ask your ophthalmologist:

1. What is the target pressure for this eye?
2. How much reduction do you expect in my case?
3. Why is DURYSTA preferable to adjusting drops or considering laser?
4. What is the condition of my corneal endothelium?
5. Does my angle, lens, or posterior capsule create additional risk?
6. Will I continue any glaucoma drops afterward?
7. When will my pressure and cornea be checked?
8. Which symptoms require an urgent call?
9. What will we do if the implant does not lower pressure enough?
10. What is the plan when its benefit fades?
11. What is my complete estimated cost, including the procedure and follow-up?

DURYSTA is best understood not as a permanent or renewable replacement for glaucoma drops, but as one possible episode in a long-term glaucoma plan. Sustained bimatoprost delivery may reduce daily dosing burden and produced meaningful average pressure reductions in trials. Yet response and duration vary, the same eye cannot be retreated, and corneal and intraocular risks require careful selection and monitoring.

The central decision is whether the expected reduction is sufficient for the individual target pressure—and whether the eye’s cornea, angle, lens, and treatment history make the finite benefit worth the risks. Patients should also know which drops to continue and what treatment is likely to follow when the effect declines. After implantation, pain, worsening redness, light sensitivity, or vision changes require prompt clinical attention.

Frequently asked questions

Can DURYSTA completely replace glaucoma eye drops?

It may replace one or more drops temporarily for some patients, but it does not reliably replace every glaucoma medication for everyone. Whether drops can be stopped depends on the pressure reached, the target pressure, glaucoma severity, and response over time. The manufacturer describes DURYSTA as nondrop delivery that works for several months, not as a guaranteed permanent replacement for all treatment (DURYSTA patient information).

Some patients may still need medication immediately after implantation or may restart it when the effect wanes. Laser or a glaucoma procedure may also be considered if pressure remains above target. Do not stop prescribed drops unless the treating ophthalmologist gives specific instructions for each medication and eye.

How long does the DURYSTA implant last?

The most defensible expectation is several months of drug delivery and pressure lowering, with substantial individual variation. The primary Phase 3 efficacy assessments were conducted through Week 12, while manufacturer summaries also describe mean pressure reduction over approximately 15 weeks (DURYSTA professional information).

Longer control extending into the 12–24-month range has been reported in subsets, but it is not guaranteed. Medication-release duration, polymer biodegradation, and duration of pressure control are separate timelines. Your ophthalmologist should judge duration by repeated pressure measurements, disease stability, and your target pressure—not by whether implant material remains visible.

Can DURYSTA be implanted again after it dissolves?

No. Under current manufacturer labeling information, DURYSTA must not be readministered to an eye that has already received it. The fact that the polymer biodegrades does not make the eye eligible for another implant. The restriction is associated with concern about corneal endothelial-cell loss and potential corneal damage after repeated administration.

Before the first implant, discuss which drops, laser treatment, or glaucoma procedure might be considered when the effect fades.

Does the DURYSTA implant need to be surgically removed?

Routine removal is generally unnecessary because the polymer biodegrades into lactic and glycolic acids over time, as described in the peer-reviewed bimatoprost implant review.

That does not guarantee that intervention will never be needed. Implant migration, inflammation, corneal effects, or another complication could require individualized management by an ophthalmologist.

Which symptoms after DURYSTA require prompt medical attention?

Contact the treating eye doctor promptly for eye pain, marked or worsening redness, light sensitivity, or any change in vision. Manufacturer safety information specifically directs patients to report redness, light sensitivity, pain, or vision changes after administration.

Sudden vision change, pain, or photophobia warrants same-day clinical attention. Follow the practice’s emergency instructions, and seek urgent eye care if severe symptoms occur and the treating clinician cannot be reached.